UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2010
Commission
File Number: 001-34541
| CHINA CORD BLOOD CORPORATION | ||
|
(Translation
of registrant’s name into English)
|
||
| 48th Floor, Bank of China Tower | ||
| 1 Garden Road | ||
| Central | ||
| Hong Kong S.A.R. | ||
| (Address of Principal Executive Offices) |
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_______________.
Other
Events
On October 7, 2010, China Cord Blood
Corporation (the “Company”) issued a press release updating the status of its
previously announced share repurchase program. A copy of the press
release is attached as Exhibit 99.1.
Exhibits
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release, dated October 7,
2010
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| CHINA CORD BLOOD CORPORATION | |||
|
|
By:
|
/s/ Albert Chen | |
| Name: | Albert Chen | ||
| Title: | Chief Financial Officer | ||
China
Cord Blood Corporation
Updates
Status Regarding Share Repurchase Program
HONG KONG, China, October 7, 2010 -
China Cord Blood Corporation (“CCBC” or “the Company”) (NYSE: CO),
the first and largest cord blood bank operator in China, today announced that
since the authorization of the stock repurchase program on September 15, 2010,
the Company has repurchased approximately 309,000 ordinary shares for
approximately US$1.6 million through October 6, 2010 at an average price per
share of US$5.32. This amount represents approximately 10.7% of the
total repurchase program authorized by CCBC’s Board of Directors, with
approximately US$13.4 million remaining in the Company’s buyback authorization
for repurchase prior to September 2011.
Ms. Ting
Zheng, Chairperson and CEO of China Cord Blood Corporation, stated, “We are
committed to enhancing shareholder value, and our actions in the past weeks
demonstrate our commitment to our shareholders and management’s confidence in
the Company’s business and future prospects. We do not believe the
current share price reflects the intrinsic value of the Company’s
business. Our expansion plan in Zhejiang province that was announced
in September, together with our intention to execute the warrant exchange offer
to simplify our capital structure, should contribute to a stronger earnings
profile. We plan to continue to grow our existing business, and at
the same time, seek opportunities to expand our business in China and the Asia
Pacific region.”
About
China Cord Blood Corporation
China
Cord Blood Corporation is the first and largest cord blood banking operator in
China in terms of geographical coverage and is the only cord blood bank operator
with multiple licenses. Under the current PRC government regulations,
only one licensed cord blood bank operator is permitted to operate in each
licensed region and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood collection,
laboratory testing, hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at
http://www.chinacordbloodcorp.com.
Safe
Harbor Statement
This
press release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events,
performance and results of operations, and underlying assumptions and other
statements that are other than statements of historical facts. These statements
are subject to uncertainties and risks including, but not limited to, product
and service demand and acceptance, changes in technology, economic conditions,
the impact of competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the Company, are expressly qualified by the
cautionary statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims any
obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof.
For
more information, please contact:
China
Cord Blood Corporation
Ms.
Joeling Law
Tel:
(+852) 3605-8180
Email:
[email protected]
ICR,
LLC
In New
York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In
Beijing: Wen Lei Zheng: +86-10-6599-7968